AbbVie's tight grip on Humira market raises concerns about biosimilars

AbbVie’s (ABBV.N) top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.